CITI
22.7.2021 08:02:06 CEST | Business Wire | Press release
Citi is pleased to announce the launch and roll out of a new global Real-Time Liquidity Sharing solution, addressing a pressing need for companies to secure improved efficiencies in liquidity and working capital.
Part of Citi’s Liquidity Optimization product suite, the new globally consistent platform is launching across six countries and jurisdictions in Asia Pacific – Australia, China, Hong Kong, New Zealand, Singapore and Taiwan – with other regions and additional markets to follow in line with client demand.
The need for improved efficiencies has been heightened by pandemic-driven remote working, rapid changes to business models and ensuing stress on liquidity. Developed in response to client demand for advanced liquidity management technology, Citi’s latest innovation enables treasurers to manage intraday liquidity in real-time.
With Citi Real-Time Liquidity Sharing, treasury teams can mobilize liquidity and fund intraday payments across multiple accounts and entities in real-time, without having to bother with physical funding of the accounts. This allows companies to maximize their working capital and eliminates the need for manual funding and forecasting, thereby saving hours of work and reducing the administrative costs associated with external and subsidiary borrowing.
Sandip Patil, Asia Pacific Head of Liquidity Management Services, Treasury and Trade Solutions, Citi, said: “We pride ourselves on our track record of working with clients to assess market conditions and deploy digital advancements to provide targeted solutions. With the launch of Citi Real-Time Liquidity Sharing, clients can benefit from real-time funding solutions even in situations where their cash flow forecasting may not go as planned. Beyond treasury automation, our new solution further complements how we are helping clients realize true eCommerce and real-time growth potential, by bringing embedded instant payments and liquidity solutions on a 24x7 basis.”
Stephen Randall, Global Head of Liquidity Management Services, Treasury and Trade Solutions, Citi, said: “The rapid development of this latest addition to our Liquidity Optimization product suite is testament to our focus on investing in digital innovations that will support clients evolving needs in a post-pandemic world. During a time of unexpected change and with the rapid acceleration of new technology adoption, we are proud to serve as a trusted advisor and partner to our clients and their treasury needs.”
Citi’s latest solution will help clients boost performance, amid unpredictable and volatile market conditions in the post-pandemic era. Citi believes that effective cash management that allows treasury and finance departments to adjust and quickly respond to dynamic business outcomes has become increasingly critical to the survival and future success of companies.
The launch of Citi Real-Time Liquidity Sharing is one of many recent innovative liquidity solutions developed and deployed by Citi’s awarding winning Liquidity Management business* to enhance its Cash Concentration product suite and expand geographical reach into markets.
Citi offers one of the most comprehensive Liquidity Management networks in the industry, supporting over 30,000 regional and global liquidity structures for clients. For more information about the advantages and availability of Citi’s suite of digital Liquidity Management tools, please contact your Citi representative.
*Citi was recently named the World’s Best Bank for Liquidity Management by Global Finance Magazine for the second year in a row – please follow link to announcement.
-ends-
About Citi’s Treasury and Trade Solutions
Citi Treasury and Trade Solutions (TTS) enables our clients' success by providing an integrated suite of innovative and tailored cash management and trade finance services to multinational corporations, financial institutions and public sector organizations across the globe. Based on the foundation of the industry's largest proprietary network with banking licenses in over 90 countries and globally integrated technology platforms, TTS continues to lead the way in offering the industry's most comprehensive range of digitally enabled treasury, trade and liquidity management solutions.
About Citi
Citi, the leading global bank, has approximately 200 million customer accounts and does business in more than 160 countries and jurisdictions. Citi provides consumers, corporations, governments and institutions with a broad range of financial products and services, including consumer banking and credit, corporate and investment banking, securities brokerage, transaction services, and wealth management.
Additional information may be found at www.citigroup.com | Twitter: @Citi | YouTube: www.youtube.com/citi| Blog: https://blog.citigroup.com/ | Facebook: www.facebook.com/citi| LinkedIn: www.linkedin.com/company/citi
View source version on businesswire.com: https://www.businesswire.com/news/home/20210721005687/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Barilla Opens Global Call for Startups Through Good Food Makers 202625.5.2026 11:47:00 CEST | Press release
The program has involved over 1,100 startups across 50+ countries, delivering 26 pilot projects. Barilla Group has opened applications for the 2026 edition of Good Food Makers, its global open innovation program designed to co-develop and test new innovative solutions with startups and innovators inside real industrial environments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521973445/en/ Since its launch in 2019, the program has involved more than 1,100 startups from over 50 countries, leading to 26 pilot projects, with over 20 projects currently active thanks to the solutions developed by the program’s alumni. This highlights the program’s role as a concrete platform for industrial scalable innovation. The 2026 edition comes at a pivotal moment for the company, following the launch of BITE (Barilla Innovation & Technology Experience), the new innovation center dedicated to developing the next generation of food prod
JEOL: Sales Launch of the Laser SEM System “LazEdge”25.5.2026 10:16:00 CEST | Press release
JEOL Ltd. (President & CEO: Izumi Oi) has developed the “LazEdge”, an SEM system equipped with a laser processing system, and begins sales on May 25, 2026. Cross-section preparation instruments such as the focused ion beam system (FIB system), are widely used in science and technology fields across research institutes, universities, and industries. In recent years, demand is increasing for a system that can process large-areas at a high speed, while achieving high-quality of the processed surface. “LazEdge” is an instrument integrating JEOL’s SEM with the laser technology proprietary of Hamamatsu Photonics K.K., and enables laser processing inside the specimen chamber of the electron microscope. This system enables high-quality cross-section specimens produced through high-speed, large-area processing to be transferred seamlessly to subsequent analyses, such as SEM observation, elemental analysis, and crystal orientation analysis, without exposure to the external environment. As a resu
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 08:00:00 CEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom